Lecanemab reaches primary clinical endpoint and all secondary clinical endpoints in the large-scale confirmatory Phase III clinical trial CLARITY.
More than 200,000 patients worldwide are urgently awaiting the emergence of new drugs.
The trials continue, as do the doubts.
Why has Alzheimer's disease become the 'graveyard of new drug development'?
With the Phase II clinical trial setback of Crenezumab, what lies ahead for Alzheimer’s disease drug development?